Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 March 2006, Vol. 107, No. 6, pp. 2486-2492.
Prepublished online as a Blood First Edition Paper on November 10, 2005; DOI 10.1182/blood-2005-08-3516.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-08-3516v1
107/6/2486    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aneja, R.
Right arrow Articles by Joshi, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aneja, R.
Right arrow Articles by Joshi, H. C.
Related Collections
Right arrow Neoplasia
Right arrow Apoptosis
Right arrow Cytoskeleton
Right arrowRelated Article in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011

Ritu Aneja, Jun Zhou, Surya N. Vangapandu, Binfei Zhou, Ramesh Chandra, and Harish C. Joshi

From the Department of Cell Biology, Emory University School of Medicine, Atlanta, GA; Department of Genetics and Cell Biology, College of Life Sciences, Nankai University, Tianjin, China; and B. R. Ambedkar Center for Biomedical Research, University of Delhi, India.

We have shown previously that EM011, a synthetic compound, binds tubulin with a higher affinity than the founding compound, noscapine, without changing total microtubule polymer mass. Now we show that EM011 is potently effective against vinblastine-resistant human lymphoblastoid line CEM/VLB100 and its parental vinblastine-sensitive line CEM. The cytotoxicity is mediated by cell cycle arrest at G2/M phase and subsequent apoptosis, as indicated by altered plasma membrane asymmetry, loss of mitochondrial transmembrane potential, activation of caspase-3, and increased DNA fragmentation. Furthermore, oral EM011 treatment of nude mice bearing human lymphoma xenografts results in pronounced tumor regression by triggering apoptosis and significantly lengthens the survival time of mice. EM011 treatment does not have obvious side effects in tissues with frequently dividing cells, such as the spleen and duodenum. In addition, EM011 does not show any toxicity in the liver, lung, heart, brain, and sciatic nerve. More importantly, EM011 does not affect hematopoiesis as determined by complete blood count profiles. These findings suggest that EM011 may be a safe and effective chemotherapeutic agent for oral treatment of drug-resistant human lymphomas. (Blood. 2006;107:2486-2492)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Microtubules, leukemia, and cough syrup
Steven Heidemann
Blood 2006 107: 2216-2217. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
R. Aneja, M. Liu, C. Yates, J. Gao, X. Dong, B. Zhou, S. N. Vangapandu, J. Zhou, and H. C. Joshi
Multidrug Resistance-Associated Protein-Overexpressing Teniposide-Resistant Human Lymphomas Undergo Apoptosis by a Tubulin-Binding Agent
Cancer Res., March 1, 2008; 68(5): 1495 - 1503.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J.-P. Liou, K.-S. Hsu, C.-C. Kuo, C.-Y. Chang, and J.-Y. Chang
A Novel Oral Indoline-Sulfonamide Agent, N-[1-(4-Methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-Isonicotinamide (J30), Exhibits Potent Activity against Human Cancer Cells in Vitro and in Vivo through the Disruption of Microtubule
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 398 - 405.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Xuan, W. Qiao, J. Gao, M. Liu, X. Zhang, Y. Cao, Q. Chen, Y. Geng, and J. Zhou
Regulation of Microtubule Assembly and Stability by the Transactivator of Transcription Protein of Jembrana Disease Virus
J. Biol. Chem., September 28, 2007; 282(39): 28800 - 28806.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Aneja, J. Zhou, B. Zhou, R. Chandra, and H. C. Joshi
Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice.
Mol. Cancer Ther., September 1, 2006; 5(9): 2366 - 2377.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Liu, R. Aneja, C. Liu, L. Sun, J. Gao, H. Wang, J.-T. Dong, V. Sarli, A. Giannis, H. C. Joshi, et al.
Inhibition of the Mitotic Kinesin Eg5 Up-regulates Hsp70 through the Phosphatidylinositol 3-Kinase/Akt Pathway in Multiple Myeloma Cells
J. Biol. Chem., June 30, 2006; 281(26): 18090 - 18097.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020